Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.64 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21612967 | 1.00 | TLR8 (0.64) | TLR8TLR7CYP1A2 | |
| SCHEMBL29758962 | 1.00 | TLR8 (0.64) | TLR8TLR7CYP1A2 | |
| SCHEMBL18109531 | 0.89 | TLR8 (0.80) | TLR8TLR7CYP1A2 | |
| SCHEMBL18109530 | 0.89 | TLR8 (0.80) | TLR8TLR7CYP1A2 | |
| SCHEMBL19432226 | 0.88 | TLR8 (0.77) | TLR8TLR7CYP1A2 | |
| SCHEMBL20991219 | 0.88 | TLR8 (0.77) | TLR8TLR7CYP1A2 | |
| SCHEMBL18109305 | 0.87 | TLR8 (0.77) | TLR8TLR7CYP1A2 | |
| SCHEMBL18109303 | 0.87 | TLR8 (0.77) | TLR8TLR7CYP1A2 | |
| SCHEMBL21611722 | 0.87 | TLR8 (0.78) | TLR8TLR7 | |
| SCHEMBL20991215 | 0.80 | TLR8 (0.76) | TLR8TLR7CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12269823-B2 | Crystal form of pyridopyrimidine derivative and preparation method thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-04-08 | — | — | US | disclosed |
| EP-4484426-A1 | PYRIMIDO AROMATIC RING COMPOUND AND USE THEREOF IN DRUG | Sunshine Lake Pharma Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| US-12162879-B2 | Pyridopyrimidine derivative, preparation method therefor and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2024-12-10 | — | — | US | disclosed |
| CN-116693527-A | Pyrimido aromatic ring compounds and application thereof in medicines | 广东东阳光药业股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023160527-A1 | PYRIMIDO AROMATIC RING COMPOUND AND USE THEREOF IN DRUG | 广东东阳光药业股份有限公司 | 2023-08-31 | — | — | WO | disclosed |
| CN-114929232-B | Crystal form of pyridopyrimidine derivative and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-115710266-A | Pyridopyrimidine derivative, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-20230058425-A1 | CRYSTAL FORM OF PYRIDOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| CN-111094289-B | Pyridopyrimidine derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-4085914-A1 | CRYSTAL FORM OF PYRIDOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2022-11-09 | — | — | EP | disclosed |
| CN-114929232-A | Crystal form of pyridopyrimidine derivative and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-113082224-A | Pyridopyrimidine derivative conjugate, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| EP-3822271-A1 | PYRIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-05-19 | — | — | EP | disclosed |
| CN-111094289-A | Pyridopyrimidine derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12269823-B2 | Crystal form of pyridopyrimidine derivative and preparation method thereof | DPYD, PNPO, PDXK | TLR8 4239/4885TLR7 3122/4885CYP1A2 57/4885 |
| US-12162879-B2 | Pyridopyrimidine derivative, preparation method therefor and medical use thereof | TLR8, TLR7, TLR1 | TLR8 1/4885TLR7 2/4885CYP1A2 1002/4885 |
| US-20230058425-A1 | CRYSTAL FORM OF PYRIDOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD THEREOF | DPYD, PNPO, PDXK | TLR8 4239/4885TLR7 3122/4885CYP1A2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.